Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Microplate Reader

By Drug Discovery Trends Editor | December 21, 2009

BioTek Instruments continues to expand its Synergy Multi-Mode Microplate Reader family with the introduction of the patent-pending Synergy H4 with Hybrid Technology. Synergy H4 combines the sensitivity of filter-based optics with the flexibility of monochromator-based optics in one compact instrument for high-performance fluorescence-based applications. This unique hybrid of both technologies provides for endless flexibility in current and future microplate-based assay choice. Additionally, Synergy H4 is compatible with BioTek’s Take3 Multi-Volume Plate for low-volume measurements down to 2 ?L.

Filter/dichroic-based fluorescence optics provide superior light filtering and purification with fast wavelength switching and read speeds. This exceptional performance is perfect for demanding applications including TR-FRET, fluorescence polarization or AlphaScreen/AlphaLISA.

Quadruple monochromator-based fluorescence optics provide the flexibility to choose any wavelength from the UV to the near infrared for a broad range of applications; and the variable bandpass selection system is ideal for spectral scanning applications. Top and bottom optics enhance assay flexibility even further.

Synergy H4 is modular, and the fully equipped configuration may be used for fluorescence intensity/FRET, time-resolved fluorescence (TRF) and TR-FRET, fluorescence polarization, AlphaScreen/AlphaLISA, Luminescence and UV-Visible Absorbance.

BioTek Instruments


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE